Literature DB >> 7752327

The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years.

S Holmäng1, H Hedelin, C Anderström, S L Johansson.   

Abstract

A retrospective study was done on 176 patients with primary stages Ta and T1 bladder cancer treated between 1963 and 1972. One patient was lost to followup after 6 years, while the remainder were followed to death or for at least 20 years. In 1993, 13 patients had no evidence of disease, 39 died of bladder cancer and 123 died of intercurrent disease. Of 77 patients with a primary noninfiltrating tumor and 99 with a primary lamina propria invasive tumor 9 (11%) and 30 (30%), respectively, died of bladder cancer. Recurrences were noted on 10 or more cystoscopic studies in 16 patients and 10 died of bladder cancer 3.5 to 19 years after the primary transurethral resection. A total of 14 patients received repeated thiotepa instillations, all continued to have recurrences and 10 subsequently died of bladder cancer. Only 1 upper tract tumor was diagnosed on routine followup excretory urography. Invasive transitional cell carcinoma of the bladder developed in only 1 of 59 patients who had been tumor-free for 5 years. The results indicate that patients with recurrences on 10 or more cystoscopic studies will continue to have recurrences until death or cystectomy. Recurrence more than 4 years after the primary tumor operation is another ominous sign. Repeated thiotepa instillations did not influence the course of the disease in patients with a history of multiple recurrences. Followup cystoscopy may be discontinued 5 to 10 years after the last recurrence, at least in patients with a solitary low grade primary tumor. Routine followup urographic studies are neither cost-effective, clinically indicated nor justified in patients with superficial bladder cancer.

Entities:  

Mesh:

Year:  1995        PMID: 7752327

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  44 in total

Review 1.  Current problems and needs in the treatment of pT1 G3 bladder carcinoma.

Authors:  Francisco Jose Martínez Portillo; Peter Alken
Journal:  Int Urol Nephrol       Date:  2002       Impact factor: 2.370

2.  Canadian guidelines for treatment of non-muscle invasive bladder cancer: a focus on intravesical therapy.

Authors:  Wassim Kassouf; Ashish M Kamat; Alexander Zlotta; Bernard H Bochner; Ronald Moore; Alan So; Jonathan Izawa; Ricardo A Rendon; Louis Lacombe; Armen G Aprikian
Journal:  Can Urol Assoc J       Date:  2010-06       Impact factor: 1.862

3.  CUA guidelines on the management of non-muscle invasive bladder cancer.

Authors:  Wassim Kassouf; Samer L Traboulsi; Girish S Kulkarni; Rodney H Breau; Alexandre Zlotta; Andrew Fairey; Alan So; Louis Lacombe; Ricardo Rendon; Armen G Aprikian; D Robert Siemens; Jonathan I Izawa; Peter Black
Journal:  Can Urol Assoc J       Date:  2015-10-13       Impact factor: 1.862

Review 4.  Chemoprevention of bladder cancer.

Authors:  Dragan J Golijanin; David Kakiashvili; Ralph R Madeb; Edward M Messing; Seth P Lerner
Journal:  World J Urol       Date:  2006-11       Impact factor: 4.226

5.  Does treatment intensity matter in superficial bladder cancer? Consensus, clinical practice, and confounding.

Authors:  Gary H Lyman; Nicole M Kuderer; Stephen J Freedland
Journal:  J Natl Cancer Inst       Date:  2009-04-07       Impact factor: 13.506

6.  NMP22 is predictive of recurrence in high-risk superficial bladder cancer patients.

Authors:  Paul Lau; Joseph L Chin; Stephen Pautler; Hassan Razvi; Jonathan I Izawa
Journal:  Can Urol Assoc J       Date:  2009-12       Impact factor: 1.862

7.  Personalized medicine in advanced urothelial cancer: when to treat, how to treat and who to treat.

Authors:  Behfar Ehdaie; Steven C Smith; Dan Theodorescu
Journal:  Can Urol Assoc J       Date:  2009-12       Impact factor: 1.862

8.  Perioperative Intravesical Chemotherapy for Patients WithNon-Muscle-invasive Bladder Cancer: Understanding the Extent of and Sources of Variation in Guideline-recommended Use.

Authors:  Devon K Check; David S Aaronson; Matthew E Nielsen; Valerie S Lee; Isaac J Ergas; Janise M Roh; Lawrence H Kushi; Li Tang; Marilyn L Kwan
Journal:  Urology       Date:  2018-10-23       Impact factor: 2.649

9.  Molecular markers in transitional cell carcinoma of the bladder: New insights into mechanisms and prognosis.

Authors:  Behfar Ehdaie; Dan Theodorescu
Journal:  Indian J Urol       Date:  2008-01

10.  CD10 expression in urothelial carcinoma of the bladder.

Authors:  Burak Bahadir; Kemal Behzatoglu; Sibel Bektas; Erol R Bozkurt; Sukru O Ozdamar
Journal:  Diagn Pathol       Date:  2009-11-16       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.